Recombinant human interleukin-2, 125Ala (Beijing SL Pharmaceutical)

重组人白细胞介素-2（125ALa）

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human interleukin-2, 125Ala (Beijing SL Pharmaceutical)
Drug Alias Name欣吉尔Xin Ji ErIL-2 (Beijing SL Pharmaceutical)
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin-2 receptor agonists
TargetsInterleukin-2 receptor
Therapy Area/IndicationsAscitesArthritis, RheumatoidLung Neoplasms +[6] 
Global Approved IndicationsAscitesArthritis, RheumatoidLung Neoplasms +[6] 
Approved Indications in ChinaAscitesArthritis, RheumatoidLung Neoplasms +[6] 
Original Approved Country/TerritoryMainland China
Original Approved Date1999/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBeijing Sl Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Sl Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsAscitesArthritis, RheumatoidLung Neoplasms +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeL03AC01
Related LinksN/A